Drug Patents: More countries to follow India's lead

Last month, Andrew Witty, the CEO of GlaxoSmithKline, called the often-cited $1 billion price tag for developing a new drug an "industry myth," based on unacceptably high research failure rates.
India is not alone. China and the Philippines amended their pharmaceutical patent laws, making it easier for those governments to take similar measures as India. Indonesia recently issued a compulsory license for a treatment for liver cancer-causing hepatitis B.

The Atlantic: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India